A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Eye Disorder
- Macular Degeneration
- Age-Related Macular Degeneration
- Dry Macular Degeneration
- Geographic Atrophy
- Blue Ash
- Colorado Springs
- Grand Rapids
- Los Angeles
- Mountain View
- Pompano Beach
- Rockville Centre
- Royal Oak
- San Francisco
- Santa Barbara
- Santa Maria
- St. Louis
- St. Petersburg
- The Woodlands
- Toms River
- Walnut Creek
- West Des Moines
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
The purpose of this study is to evaluate the long-term safety and tolerability of intravitreal (ITV) injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who completed the parent study (NCT03972709/GR40973).
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Completed the parent study (NCT03972709/GR40973) through the Week 76 visit without early treatment discontinuation
- Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit acceptable fundus imaging.
Ocular Inclusion Criteria: Study Eye - If the study eye best corrected visual acuity (BCVA) letter score is ≥69 letters (Snellen equivalent of 20/40 or better), the non-study eye must have a BCVA letter score of ≥44 letters (Snellen equivalent of 20/125 or better) on visit Day 1 of the open label extension (OLE)/Week 76 of parent study.
Ocular Inclusion Criteria: Non-Study Eye
- The non-study eye must have a BCVA letter score of ≥44 letters (Snellen equivalent of 20/125 or better) if the study eye BCVA letter score is ≥69 letters (Snellen equivalent of 20/40 or better) on visit Day 1 OLE/Week 76 of parent study.
Ocular Exclusion Criteria:
- Active uveitis and/or vitritis (grade trace or above) in either eye
- Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
- Active or history of choroidal neovascularization (CNV) in study eye that requires anti-vascular endothelial growth factor (anti-VEGF) treatment
- Active or recent history (i.e., since enrollment in parent study) of optic neuritis in either eye
- Retinal pigment epithelium (RPE) tear that involves the macula in either eye
- Moderate or severe non-proliferative diabetic retinopathy in either eye
- Proliferative diabetic retinopathy in either eye
- Central serous retinopathy in either eye
- Recent history of recurrent infectious or inflammatory ocular disease in either eye
- Recent history of idiopathic or autoimmune-associated uveitis in either eye
- Any concurrent ocular or intraocular condition in the study eye that contraindicates the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications.
For the latest version of this information please go to www.forpatients.roche.com